115370 Results

People

  1. Ladanyi
    Ladanyi
  2. Motzer
    Motzer
  3. Reuter
    Reuter
  4. Scher
    Scher
  5. Brennan
    Brennan
  6. Giralt
    Giralt
  7. Gonen
    Gonen
  8. Perales
    Perales
  9. Hudis
    Hudis
  10. Jarnagin
    Jarnagin

Groups

  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)
  7. Center for Hematologic Malignancies (13263)
  8. Hematologic Malignancies, Division of (13087)
  9. Sloan Kettering Institute Postdocs (12936)
  10. Department of Pathology and Laboratory Medicine (12615)
Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Long-term efficacy and safety of obecabtagene autoleucel (obe-cel) in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia ([R/R B-ALL]; Pooled analysis from ALLCAR19 and FELIX phase Ib studies) or other B-cell malignancies (ALLCAR19 extension study)
    Meeting Abstract

    Roddie, C.; Tholouli, E.; Shaughnessy, P.; Jabbour, E.; Logan, A. C.; Hodby, K.; Mountjoy, L.; Bloor, A. J. C.; Irvine, D.; Linch, D. C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib in richter transformation: Updated efficacy and safety results with 18-month median survival follow-up from the phase 1/2 BRUIN study
    Meeting Abstract

    Wierda, W. G.; Shah, N. N.; Cheah, C. Y.; Lewis, D.; Hoffmann, M. S.; Coombs, C. C.; Lamanna, N.; Ma, S.; Jagadeesh, D.; Munir, T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Impact of large cells and Ki-67% on outcomes in patients with newly diagnosed marginal zone lymphoma - Results from a multicenter cohort study
    Meeting Abstract

    Epperla, N.; Grover, N. S.; Annunzio, K.; Watkins, M. P.; Torka, P.; Karmali, R.; Anampa-Guzmán, A. C.; Oh, T. S.; Reves, H.; Tavakkoli, M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Results from an intergroup randomized phase II study of the combinations of ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed/refractory classic Hodgkin lymphoma: A trial of the ECOG-ACRIN Research Group (E4412)
    Meeting Abstract

    Diefenbach, C. S.; Jegede, O.; Ansell, S. M.; Steidl, C.; Natkunam, Y.; Scott, D. W.; Mehta-Shah, N.; Amengual, J. E.; Forlenza, C. J.; Cole, P. D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Long-term follow up for SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with philadelphia-chromosome (Ph) positive acute lymphoblastic leukemia (ALL)
    Meeting Abstract

    Advani, A. S.; Moseley, A. B.; O'Dwyer, K. M.; Wood, B. L.; Park, J. H.; Wieduwilt, M. J.; Jeyakumar, D.; Yaghmour, G.; Atallah, E. L.; Gerds, A. T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Progression-free survival (PFS) and toxicity with nivolumab-AVD compared to brentuximab vedotin-AVD in pediatric advanced stage (AS) classic Hodgkin lymphoma (cHL), results of SWOG S1826
    Meeting Abstract

    Castellino, S. M.; Li, H.; Herrera, A. F.; Punnett, A.; Leblanc, M.; Parsons, S. K.; Hodgson, D.; Keller, F.; Drachtman, R. A.; Lamble, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real world outcomes with idecabtagene vicleucel (ide-cel) CAR-T cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Sidana, S.; Ahmed, N.; Akhtar, O. S.; Heim, M.; Brazauskas, R.; Hansen, D. K.; Ferreri, C.; Freeman, C. L. L.; Afrough, A.; Anderson, L. D. Jr; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early-stage classical Hodgkin lymphoma (SGN35-027 Part C)
    Meeting Abstract

    Abramson, J. S.; Straus, D. J.; Bartlett, N. L.; Burke, J. M.; Lynch, R. C.; Domenech, E. D.; Hess, B.; Schuster, S. R.; Linhares, Y.; Ramchandren, R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy of venetoclax and selinexor in combination with chemotherapy in pediatric and young adult patients with relapsed or refractory acute myeloid leukemia: SELCLAX
    Meeting Abstract

    Zarnegar-Lumley, S.; Karol, S. E.; Pounds, S.; Klco, J. M.; Sulis, M. L.; Kuo, D. J.; Heym, K. M.; Ludwig, K.; Stevens, A. M.; Alexander, T. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Phase 1/2 study of TP-3654, a selective PIM1 kinase inhibitor: Preliminary data showed clinical activity and cytokine reductions in relapsed/refractory myelofibrosis patients
    Meeting Abstract

    Rein, L. A. M.; El Chaer, F.; Yuda, J.; Shimoda, K.; McCloskey, J.; Takami, A.; Haque, T.; Ichii, M.; Shirane, S.; Fukaya, M.; more...
    Blood (2023)

    Fulltext@MSK | Save